Inclusion Criteria

Inclusion criteria:

- In the dose escalation part: patients with High MET tumor expression, evaluable or
measurable solid tumors for which no standard therapy is available.

- In the expansion cohorts: in the first cohort, patients with diagnosed MET- gene
amplified and measurable tumors will be eligible. In the second cohort, patients with
P-MET positive measurable solid tumor without MET-gene amplification will be
eligible.

Exclusion criteria:

- Patient less than 18 years old.

- ECOG performance status >2.

- Any serious active disease or co-morbid condition, which, in the opinion of the
investigator, may interfere with the safety or the compliance with the study.

- Poor bone marrow reserve as defined by absolute neutrophils count <1.5 x 109/L or
platelets <100 x 109/L.

- Poor organ function as defined by one of the following:

- Total bilirubin >1.5 x ULN

- AST, ALT, alkaline phosphatase >2.5 x ULN or >5 x ULN in case of documented liver
metastasis

- Serum creatinine >1.5 x ULN or

- Serum creatinine between 1.0 and 1.5 x UNL associated with calculated creatinine
clearance <60 mL/min

- Proteinuria > 500 mg/24H

- Pregnant or breast-feeding women.

- No use of effective birth control methods, when applicable.

- No measurable or evaluable tumor lesion in the Dose Escalation part, and no
measurable lesions in the expansion cohorts.

- Brain metastasis (other than totally resected or previously pre-irradiated and no
progressive/ relapsing) or lepto-meningeal carcinomatosis.

- No resolution of any specific toxicities (excluding alopecia) related to any prior
anti- cancer therapy to grade ≤1 according to the NCI CTCAE v.4.03.

- Wash out period of less than 2 weeks from previous antitumor therapy or any
investigational treatment, (and less than 6 weeks in case of prior nitroso-urea and
or mitomycin C treatment).

- Any surgery with major risk of bleeding performed less than 10 days prior to study
treatment administration.

- Any other severe underlying medical conditions, which could impair the ability to
participate in the study or the interpretation of its results.

- Patients treated with potent CYP3A inhibitor.

- Patients treated with CYP3A inducers.

- Known hypersensitivity or any adverse event related to the study drug excipient.

- Prior treatment with any MET inhibitor compound (selective or not).

The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.